Cagrilintide
Also known as: AM833
limited human dataNot FDA approvedResearch only
Published Dose Range
Low0.3 mg/week
Typical1.2-2.4 mg/week
High4.5 mg/week
Long-acting amylin analog. Investigational — Phase 3 trials ongoing, often co-administered with Semaglutide (CagriSema). Dose range reflects published trial protocols.
Published Cycle Range
No published cycle data available.
Administration
Routessubcutaneous
FrequencyOnce weekly
Preferred timingSame day each week
Limited published titration guidance outside trial protocols.
Safety Profile
Contraindications
- • Severe gastroparesis
- • History of hypersensitivity to amylin analogs
Common side effects
- • Nausea
- • Vomiting
- • Decreased appetite
- • Injection site reactions
Serious risks
- • Long-term safety not established
- • Additive GI toxicity when combined with GLP-1 agonists
Drug interactions
- • Delays gastric emptying
Requires monitoring
- • HbA1c if diabetic
- • Weight
Pregnancy / breastfeeding
Contraindicated — investigational
Common Misconceptions
- Not FDA approved — trial-stage compound
- Effective primarily in combination with GLP-1 agonists — monotherapy effect is smaller
Commonly Stacked With
Semaglutide
- GI side effects are additive when combined with GLP-1 agonists — titrate slowly
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.